About Us
About Disruptive Pharma
Formulite®
Business model
The Board
Management
Investor Relations
Financial calender
Financial reports
Share information
Corporate governance
General meetings
Rights Issue 2025
Newsroom
Press releases
Analyses and presentations
Subscribe
Contact
Swe
Search
Advancing oral drug development with Formulite
®
Guard Therapeutics is acquiring Disruptive Pharma and changing its name to Disruptive Pharma AB
Read More
Latest Press Releases
Guard Therapeutics Completes Reverse Takeover of Disruptive Pharma and Executes In-Kind Share Issue
(regulatory)
Read More
Guard Therapeutics Receives Conditional Approval for Continued Listing on Nasdaq First North Growth Market and Publishes Company Description
(regulatory)
Read More
Guard Therapeutics Initiates Transaction Process for the GTX Platform
Read More
Press releases
27 Jul 2026 · Regulatory information
Guard Therapeutics Completes Reverse Takeover of Disruptive Pharma and Executes In-Kind Share Issue
Read More
16 Jul 2026 · Regulatory information
Guard Therapeutics Receives Conditional Approval for Continued Listing on Nasdaq First North Growth Market and Publishes Company Description
Read More
12 Jun 2026
Guard Therapeutics Initiates Transaction Process for the GTX Platform
Read More
10 Jun 2026 · Regulatory information
Guard Therapeutics has entered into a conditional agreement for a reverse takeover with Disruptive Pharma
Read More
Show more
In focus
16 Sep 2025 / Presentation
CEO Tobias Agervald appears on BiotechTV
Read More
17 Oct 2024 / Presentation
Guard presents at Redeye Theme "Cardiovascular & Metabolic Diseases Event 2024"
Read More
23 Sep 2024 / Presentation
CEO Tobias Agervald appears on BiotechTV
Read More
19 Sep 2024 / Presentation
Presentation at Pareto Securities' 15th Annual Healthcare Conference
Read More
Show more
Upcoming events
20 Aug 2026
Interim Report January–June 2026
Read More
12 Nov 2026
Interim Report January–September 2026
Read More
18 Feb 2027
Year-end Report 2026
Read More
Show more